About SciClone Pharmaceuticals
SciClone Pharmaceuticals is a publicly listed company based in Shanghai (China) founded in 1989, and was acquired by BOC Investment in June 2017. Specialty biopharma company that develops and commercializes specialist-oriented drugs. SciClone Pharmaceuticals has completed 1 acquisition, including NovaMed Pharmaceuticals. Its focus areas include Diversified Pharmaceuticals. Its legal entity is SCICLONE PHARMACEUTICALS INC.
Company details
Sciclone is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. It has 7 marketed products in oncology and 1 product (Zadaxin) for HBV, HCV, immune system enhancement and sepsis. Product pipeline includes rapidfilm (CFDA reviewing CTA) and SGX942 (phase 2) in oncology; angiomax (CFDA review), neucardin (phase 3) and cleviprex (CTA application filed) in cardiovascular segment; and loramyc (In clinical testing) and vibativ (CTA application planning) in anti-infectives category
- Headquarters Shanghai, China
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website sciclone.com
- Social LinkedIn
- Acquired by BOC Investment (Jun 2017)
- Legal Name Sciclone Pharmaceuticals Inc
- Annual Revenue$160.1 M (USD)2as on Dec 31, 2016
- Net Profit$30.73 M (USD)4as on Dec 31, 2016
- EBITDA$33.24 M (USD)11as on Dec 31, 2016
- InvestorsAscendent Capital Partners
& 3 more
- Investments & Acquisitions
- Acquired byBOC Investment
(Jun 2017)
Investors in SciClone Pharmaceuticals
SciClone Pharmaceuticals has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Ascendent Capital Partners, GL Capital and BOC Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| ascendentcp.com | ||||
Private equity investments in China are managed by BOC Investment. | bocgi.com | Xicheng, China | ||
Private equity and private debt firm focused on multiple sectors | cdhfund.com | Kowloon, China | ||
Real estate syndication platform for group investments in properties generating passive income. | 2016 | glcapital.io | Columbia, United States |
Investor details for SciClone Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SciClone Pharmaceuticals
15 people are tracked at SciClone Pharmaceuticals (10 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Peter Shao | Vice President, Head of Technical Operations | Leadership |
Jiting Yan | BD Director | Leadership |
Shidong Zhang | VP, Marketing & Medical Affair | Leadership |
Emil Lai | Regional Director - International Sales | Leadership |
Bokang Zhou | Vice President of Commerce | Leadership |
Cecile Pan | VP of Finance, CFO | Leadership |
宏 赵 | President&CEO | Leadership |
岩松（Phil） 常 | Vice President and General Manager of ONCO | Leadership |
Cristina Gargiuolo | Director Quality Assurance | Leadership |
Bin Peng | Senior Director, CMC | Leadership |
Elisabetta Perazzi | Senior Manager Of Manufacturing Science & Technology | Team |
Polly Wong | Accounting Manager | Team |
Tuyen Pham | Sales Manager | Team |
Celine Tay | Senior Supply Chain Manager | Team |
Willy Toh | Supply Chain Manager | Team |
Complete people profiles for SciClone Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SciClone Pharmaceuticals
SciClone Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NovaMed Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for oncology, cardiovascular, and CNS disorders are developed. | novamed.com.cn | Shanghai, China | 2005 | Apr 2011 | $61.8M |
Complete acquisition details for SciClone Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of SciClone Pharmaceuticals
4 dated milestones of SciClone Pharmaceuticals across 32 years, from founding to its latest funding, stage changes and deals.
- Founded SciClone Pharmaceuticals is founded.
- Acquisition Acquires NovaMed Pharmaceuticals.
- Exit Acquired by BOC Investment.
- IPO Lists on the stock exchange (IPO).
Web traffic of SciClone Pharmaceuticals
Websites that share an audience with SciClone Pharmaceuticals (sciclone.com).
Websites whose visitors overlap most with SciClone Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hgsi.com | 100% | View details | |||
| shanthabiotech.com | 100% | View details | |||
| pharming.com | 100% | 16.8K | #1,623,426 | View details | |
aplagen.com | aplagen.com | 100% | – | ||
| biotech-concepts.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for SciClone Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sciclone Pharmaceuticals
Complete news archive for SciClone Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SciClone Pharmaceuticals
SciClone Pharmaceuticals was founded in 1989.
SciClone Pharmaceuticals is headquartered in Shanghai, China.
Annual revenue of SciClone Pharmaceuticals is $160.1M as on Dec 31, 2016.
Sciclone is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. It has 7 marketed products in oncology and 1 product (Zadaxin) for HBV, HCV, immune system enhancement and sepsis. Product pipeline includes rapidfilm (CFDA reviewing CTA) and SGX942 (phase 2) in oncology; angiomax (CFDA review), neucardin (phase 3) and cleviprex (CTA application filed) in cardiovascular segment; and loramyc (In clinical testing) and vibativ (CTA application planning) in anti-infectives category.
SciClone Pharmaceuticals has made 1 acquisition, including NovaMed Pharmaceuticals.
SciClone Pharmaceuticals has 4 investors. Key investors include Ascendent Capital Partners, GL Capital, BOC Investment, and CDH.
SciClone Pharmaceuticals operates through Sciclone Pharmaceuticals Inc.
Yes. SciClone Pharmaceuticals was acquired by BOC Investment in June 2017.